Iman Khani Farahani

This study shows that DTP cells in EGFR-mutant lung cancer drive immunosuppression through YAP/TEAD activity, and co-targeting YAP/TEAD improves EGFR TKI therapy efficacy.

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

This study uses phosphoproteomic analysis in zebrafish to show that ErbB inhibitors affect multiple signaling pathways, leading to similar physiological phenotypes.